The use of active surveillance or watchful waiting increased by more than twofold overall between 2010 and 2020 among patients with intermediate-risk prostate cancer. Current guidelines support active ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

SBRT reduced biochemical failure and acute GU toxicity compared with HDR brachytherapy in intermediate-risk prostate cancer. Read more about the findings.

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

New Corewell Health™ research suggests an MRI scan can help predict whether patients with intermediate-risk prostate cancer (cancer confined to the entire prostate) may have more aggressive cancer in ...

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

It’s the second most common type of cancer among men and affects 1 in every 8 men in the United States. September is Prostate Cancer Awareness Month, and the American Cancer Society says this type of ...